TY - JOUR
T1 - Delineating antibody recognition against Zika virus during natural infection
AU - Yu, Lei
AU - Wang, Ruoke
AU - Gao, Fei
AU - Li, Min
AU - Liu, Jianying
AU - Wang, Jian
AU - Hong, Wenxin
AU - Zhao, Lingzhai
AU - Wen, Yingfen
AU - Yin, Chibiao
AU - Wang, Hua
AU - Zhang, Qi
AU - Li, Yangyang
AU - Zhou, Panpan
AU - Zhang, Rudian
AU - Liu, Yang
AU - Tang, Xiaoping
AU - Guan, Yongjun
AU - Qin, Cheng Feng
AU - Chen, Ling
AU - Shi, Xuanling
AU - Jin, Xia
AU - Cheng, Gong
AU - Zhang, Fuchun
AU - Zhang, Linqi
N1 - Funding Information:
The project was supported by Guangzhou Science and Technology Program for Public Wellbeing (2014Y2-00185, 2014Y2-00550, and 201508020263), the Special Program of Guangdong Provincial Department of Science and Technology (2016A020248001), the Guangzhou Health Care and Cooperation Innovation Major grant, the National Natural Science Foundation Award (81530065 and 81590762), the National Key Plan for Scientific Research and Development of China (2016YFC1200902), and Ministry of Science and Technology of China (2014CB542500-03).
Publisher Copyright:
© 2017 American Society for Clinical Investigation. All rights reserved.
PY - 2017/6/15
Y1 - 2017/6/15
N2 - Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that shares a considerable degree of homology with dengue virus (DENV). Here, we examined longitudinal antibody response against ZIKV during natural infection in 2 convalescent individuals. By decomposing the antibody recognition into DI/DII and DIII of the E glycoprotein, we showed their development in humans followed a spatiotemporal hierarchy. Plasma binding to DI/DII appeared to peak and wane during early infection with extensive cross-reactivity with DI/DII of DENV. Binding to DIII, however, peaked early but persisted months into the infection without detectable cross-reactivity with DIII of DENV. A clear trend of increase in DIII-specific neutralizing activity was observed over the course of infection. mAbs isolated during early infection are largely DI/DII specific, weakly neutralizing, and highly cross-reactive with DENV, while those from later infection are more diverse in recognition, potently neutralizing, and ZIKV specific. The most potent neutralizing mAb targeting the DIII provided 100% protection in mice from lethal ZIKV infection and could therefore serve as a promising candidate for antibody-based therapy and prevention. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines.
AB - Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that shares a considerable degree of homology with dengue virus (DENV). Here, we examined longitudinal antibody response against ZIKV during natural infection in 2 convalescent individuals. By decomposing the antibody recognition into DI/DII and DIII of the E glycoprotein, we showed their development in humans followed a spatiotemporal hierarchy. Plasma binding to DI/DII appeared to peak and wane during early infection with extensive cross-reactivity with DI/DII of DENV. Binding to DIII, however, peaked early but persisted months into the infection without detectable cross-reactivity with DIII of DENV. A clear trend of increase in DIII-specific neutralizing activity was observed over the course of infection. mAbs isolated during early infection are largely DI/DII specific, weakly neutralizing, and highly cross-reactive with DENV, while those from later infection are more diverse in recognition, potently neutralizing, and ZIKV specific. The most potent neutralizing mAb targeting the DIII provided 100% protection in mice from lethal ZIKV infection and could therefore serve as a promising candidate for antibody-based therapy and prevention. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines.
UR - http://www.scopus.com/inward/record.url?scp=85040226711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040226711&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.93042
DO - 10.1172/jci.insight.93042
M3 - Article
C2 - 28614803
AN - SCOPUS:85040226711
SN - 0021-9738
VL - 2
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 12
M1 - e93042
ER -